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Marianne S. Fjording3, Jørgen Finnemann3, Tine Skak-Nielsen3, Søren R. Paludan4 and Lars Iversen1
Mitogen- and stress-activated protein kinase 1 (MSK1) is a downstream target of both the p38 and extracellular
signal-regulated kinase 1/2 (ERK1/2) mitogen-activated protein kinases (MAPKs). MSK1 stimulates transcription
of different pro-inflammatory genes through activation of transcription factors. The purpose of this study was to
investigate the expression and activation of MSK1 in lesional psoriatic skin and its role in cytokine production in
cultured normal human keratinocytes. Western blotting revealed a consistent and significant increase in
phosphorylated (activated) MSK1(Ser376) in lesional psoriatic skin. Immunofluorescence staining revealed the
phosphorylated MSK1(Thr581) to be localized in the basal layers of the epidermis in lesional psoriatic skin. No
staining was found in non-lesional psoriatic skin. Cultured human keratinocytes incubated with anisomycin or
IL-1b resulted in the phosphorylation of the p38 MAPK and MSK1(Ser376). MSK1(Ser376) phosphorylation was
inhibited by pre-incubation with the p38 inhibitor SB 202190. Transfection of the keratinocytes with specific
MSK1 small interfering RNA resulted in 80% reduction of MSK1 expression and 51, 40, and 31% decrease in IL-6,
IL-8, and tumor necrosis factor-a protein production, respectively. This study demonstrates for the first time the
expression of MSK1 in epidermal keratinocytes and increased activation focally in psoriatic epidermis. As MSK1
regulates the production of pro-inflammatory cytokines, it may play a role in the pathogenesis of psoriasis.
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INTRODUCTION
Psoriasis is a chronic immune-mediated inflammatory dis-
ease. The prevalence rates are quoted to be around 2%
(Christophers, 2001). It is characterized by hyperproliferation
and abnormal differentiation of the keratinocytes and
infiltration of the skin by activated T cells (Krueger et al.,
1990). Abnormalities in several signaling pathways and in the
expression or activation of different transcription factors in
psoriatic keratinocytes have been hypothesized to play a role
in the pathophysiology of psoriasis (McKenzie and Sabin, 2003).
Intracellular protein kinase cascades transduce signals
from the cell surface into changes in gene expression.
Thereby, they contribute to the regulatory mechanisms
controlling cell proliferation, differentiation, and apoptosis.
The mitogen-activated protein kinase (MAPK) cascades are
among the best characterized of these intracellular protein
kinase cascades (Robinson and Cobb, 1997). The p38 MAPK
and the extracellular signal-regulated kinase (ERK) 1 and
ERK2 MAPKs are two of the best-studied MAPKs.
Mitogen- and stress-activated protein kinase 1 (MSK1) is a
downstream effecter kinase of both the p38 and the ERK1/2
MAPKs. MSK1 is predominantly a nuclear enzyme (Deak
et al., 1998). It has been shown to phosphorylate various
transcription factors including cAMP-response element-bind-
ing protein (CREB) (Deak et al., 1998), activation transcript-
ion factor 1 (ATF1) (Wiggin et al., 2002), and the p65 subunit
of NF-kB at Ser276 (Vermeulen et al., 2003). Lipopolysac-
charide-induced transcription of cyclooxygenase 2 and IL-1b
is strongly inhibited by the two nonspecific MSK1 inhibitors
Ro318220 and H89 in RAW264 macrophages (Caivano and
Cohen, 2000), suggesting MSK1 to be involved in the
regulation of the expression of these proteins. Another study
demonstrated, that IL-6 mRNA levels induced by tumor
necrosis factor (TNF) were reduced in the presence of
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MSK1/2 double knockout mice are viable and fertile and
have no obvious health problems (Wiggin et al., 2002).
Embryonic fibroblasts derived from these mice showed a
complete abolishment of phosphorylation of CREB and ATF1
in response to anisomycin and UV (Arthur and Cohen, 2000;
Wiggin et al., 2002).
We recently reported that the activity of the p38 MAPK
and to a lesser degree ERK1/2 MAPKs are increased in
lesional psoriatic skin compared with non-lesional skin
(Johansen et al., 2005b). The p38 MAPK may, therefore, play
an important role in the pathogenesis of psoriasis and other
inflammatory conditions. Different inhibitors of the p38
MAPK have been identified and are currently tested in
clinical trials of rheumatoid arthritis (Saklatvala, 2004). As the
p38 MAPK signaling pathway may serve as a target in the
treatment of various inflammatory conditions including
psoriasis, it is of interest to further characterize the role of
novel p38 MAPK downstream targets in psoriasis.
In this study the localization and activation of MSK1 in
lesional psoriatic skin was compared with non-lesional
psoriatic skin. We show that the phosphorylated (activated)
form of MSK1(Ser376) is significantly increased in lesional
psoriatic skin compared with non-lesional skin. We do also,
for the first time, use specific MSK1 small interfering RNA
(siRNA), to inhibit MSK1 expression, in cultured normal
human keratinocytes. This resulted in a significant decrease
in the phosphorylation of CREB and in anisomycin-induced
expression of the pro-inflammatory cytokines IL-6, IL-8, and
TNF-a indicating a role for MSK1 in the production of these
cytokines. No alteration was found in anisomycin-induced
IFN-g or IL-1b production. In conclusion, we identify MSK1
as a key kinase in lesional psoriatic skin-regulating IL-6, IL-8,
and TNF-a expression in human skin, and therefore, the MSK1
might serve as a putative target in the treatment of psoriasis.
RESULTS
MSK1 expression and activation in lesional psoriatic skin
compared with non-lesional psoriatic skin
The phosphorylated Ser376 and total protein expression
levels of MSK1 in psoriatic skin were determined by Western
blotting. Whole-cell extracts from lesional and non-lesional
psoriatic skins were isolated and six psoriatic patients were
examined (Figure 1a). Analysis of the band intensity showed a
significant increase (3.7-fold, Po0.05) in MSK1 Ser376
phosphorylation, and in lesional psoriatic skin compared
with non-lesional psoriatic skin (Figure 1a and b). No
significant change was found in the band intensity of total
MSK1 protein (Figure 1a and c). Equal protein loading
was confirmed by assessing the protein level of b-actin
(Figure 1a).
Immunofluorescence localization of activated MSK1 in
psoriatic skin
We investigated the localization of the Thr581 phosphory-
lated form of MSK1 by performing immunofluorescence
imaging of lesional psoriatic skin and non-lesional psoriatic
skin, from six psoriatic patients, obtained as punch biopsies.
In all samples studied, a strong staining of Thr581 phospho-
MSK1 (activated MSK1) was seen in the lesional psoriatic
skin. The staining was present locally in the basal and supra-
basal layers of the epidermis (Figure 2g and h). The Thr581
phospho-MSK1-positive cells stained positive to keratin 14
(Figure 2e and h), a specific marker for keratinocytes. The
nuclei were localized with 40,6-diamidine-20-phenylindole
dihydrochloride (Figure 2f and h). The Thr581-phosphory-
lated MSK1 was mainly localized in the nucleus of these
keratinocytes, but some staining was also seen in the
cytoplasm (Figure 2h and i). The staining of keratin 14 and
the nuclei in non-lesional psoriatic skin is seen in Figure 2a
and b, respectively. No staining of phospho-MSK1(Thr581) was
detected in the non-lesional psoriatic skin (Figure 2c and d).
IL-1b and anisomycin induces activation of MSK1(Ser376),
CREB, and ATF1 in normal human keratinocytes in vitro
To study the activation of MSK1(Ser376) in epidermal
keratinocytes, cultured normal human keratinocytes were
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Figure 1. MSK1 activities in lesional and non-lesional psoriatic skin. Western
blotting of equivalent amounts of whole-cell protein extracts from non-
lesional and lesional psoriatic skin was made. (a) The proteins were loaded
onto a 10–20% gradient gel and blotted to a nitrocellulose membrane. The
separated proteins were probed with anti-phospho-MSK1(Ser376), or anti-
MSK1. Equal loading was confirmed by incubating with anti-b-actin.
Densitometric analysis of the band intensity from six patients was carried out
and the intensity is presented as mean7SD (arbitrary units). The level of
b-actin was used for normalization. (b) Phospho-MSK1(Ser376) and (c) total
MSK1 in non-lesional psoriatic skin compared with lesional psoriatic skin.
*Po0.05.
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incubated with IL-1b (10 ng/ml) or the specific activator
of p38 MAPK anisomycin (0.5 mg/ml), for various times
(Figure 3). The levels of phosphorylated-p38 MAPK, -ERK1/
2, -MSK1(Ser376), -CREB, and -ATF1 were determined
by Western blotting of whole-cell extracts (40 mg of protein).
Analysis of the band intensity was carried out for all
proteins investigated. A significant increase (Po0.05) in
the phosphorylated form of ERK1/2, p38, MSK1(Ser376),
CREB, and ATF1 was seen after 5 minutes incubation with
IL-1b. The level of phosphorylated ERK1/2 and p38 peaked
at 5 minutes, whereas the level of phosphorylated
MSK1(Ser376), CREB, and ATF1 peaked at 15 minutes
(Figure 3).
Stimulation with anisomycin lead to a significant phos-
phorylation (Po0.05) of p38 MAPK, MSK1(Ser376), CREB,
and ATF1 seen after 5 minutes, as determined by analysis of
band intensity, and it was consistent also after 60 minutes
(Figure 3). The phosphorylation of these kinases peaked for
all of them at 5–30 minutes. The ERK1/2 was not significantly
activated by anisomycin.
Equal loading was confirmed by incubation with an
anti-MSK1 antibody (Figure 3).
Pre-incubation with SB 202190 significantly inhibits the
activation of MSK1(Ser376), CREB, and ATF1 induced by
IL-1b and anisomycin
To study the role of p38 in the MSK1 activation, cultured
normal human keratinocytes were pre-incubated with SB
202190 (10 mM). The levels of phosphorylated-p38 MAPK,
-MSK1(Ser376), -CREB, and -ATF1 were determined by
Western blotting of whole-cell extracts (40 mg of protein).
Analysis of the band intensity was carried out for all the
proteins investigated. Pre-incubation with SB 202190 for
30 minutes before stimulation with either IL-1b (10 ng/ml) or
anisomycin (0.5 mg/ml) significantly inhibited (Po0.05) the
level of phosphorylated-p38 MAPK at 5 minutes of stimula-
tion and -MSK1(Ser376), -CREB and -ATF1 at 15 minutes of
stimulation (Figure 4a).
To study the role of ERK1/2 in the anisomycin and IL-1b-
induced MSK1 activation, cultured normal human keratino-
cytes were pre-incubated with PD 98059 (50 mM), a specific
inhibitor to ERK1/2 (Pang et al., 1995). The levels of
phosphorylated-ERK1/2 MAPKs, -MSK1, -CREB, and -ATF1
were determined by Western blotting of whole-cell extracts
(40 mg of protein). Analysis of the band intensity was carried
out for all the proteins investigated. Pre-incubation with PD
98059 (50 mM) for 30 minutes before incubation with either
IL-1b (10 ng/ml) or anisomycin (0.5mg/ml) significantly inhi-
bited (Po0.05) the level of phosphorylated ERK1/2 at 5 minutes
of stimulation. The level of phosphorylated-MSK1(Ser376),
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Figure 2. Localization of activated MSK1 in lesional and non-lesional
psoriatic skin. Immunofluorescence staining of phospho-MSK1(Thr581) in
(a–d) non-lesional and (e–h) lesional psoriatic skin. Green staining (Alexa
Fluor 488) stains keratin-14, blue color (40,6-diamidine-20-phenylindole
dihydrochloride (DAPI)) stains the nucleus, and red color (Alexa Fluor 594)
stains the activated MSK1. The orange color confirms the localization of
activated MSK1 in the cytoplasm of specific keratinocytes. Figures show
representatives fluorescence images of six psoriatic patients investigated.
Original magnification (a–h) 390 and (i) 1,590.
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Figure 3. Effects of anisomycin and IL-1b on ERK1/2, p38, MSK1, CREB, and
ATF1 phosphorylation. Cultured human keratinocytes were stimulated with
IL-1b (10 ng/ml) or anisomycin (0.5 mg/ml) for 5, 15, 30, and 60 minutes.
Whole-cell extracts (50 mg of protein) were isolated and separated by SDS-
PAGE on a 10–20% gradient gel. After electroblotting, the separated proteins
were probed with anti-phospho-ERK1/2 (first serial of bands), anti-phospho-
p38 (second serial of bands), anti-phospho-MSK1(Ser376) (third serial of
bands), or anti-phospho-CREB/ATF1 (fourth serial of bands). Equal loading
was confirmed by incubating with an anti-MSK1 antibody (last band).
Representative gels of at least three different experiments are shown.
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-CREB, and -ATF1 were not significantly inhibited at
15 minutes of stimulation (Figure 4b). However, when the
cells were stimulated by IL-1b (Figure 4b), a slight but not
significant inhibition of phosphorylated-MSK1(Ser376),
-CREB, and -ATF1 was seen. Equal loading was confirmed
by incubation with an anti-MSK1 antibody (Figure 4a and b).
MSK1 siRNA transfection reduces MSK1 protein content and
the activation of CREB
To study the effect of suppression of the MSK1 gene
expression in cultured normal human keratinocytes, the cells
were transfected with MSK1 siRNA for 48 hours before
stimulation with anisomycin (0.5 mg/ml) for 15 minutes. The
levels of total MSK1, MSK2, phosphorylated-CREB, and
phosphorylated-ATF2 were determined by Western blotting
of whole-cell extracts (40 mg of protein). Analysis of the band
intensity was carried out for all the proteins investigated. The
mean total MSK1 protein content in the keratinocytes was
reduced by approximately 80% (Po0.05) in the transfected
cells compared to keratinocytes transfected with siControl
(Figure 5). The level of phospho-CREB was reduced by
approximately 50% (Po0.05), whereas no alterations were
seen in phospho-ATF2, or total MSK2 protein. The levels of
MK2 and b-actin were also examined and no alterations were
found (data not shown). The MSK1 siRNA-treated cells were
examined for off-target effects (activation of the interferon
system) checked by analyzing eIF2a, STAT1, and OAS2 by
real-time quantitative PCR (real-time qPCR). No activation of
these IFN-associated anti-viral pathway genes was seen (data
not shown).
The anisomycin-induced IL-6, IL-8, and TNF-a production is
regulated through MSK1
To demonstrate the role of anisomycin in IL-6, IL-8, and TNF-a
production in human keratinocytes, we stimulated the keratino-
cytes for 4, 6, and 12 hours. A significant upregulation in
expression levels for these cytokines was seen at 4, 6, and
12 hours (Figure 6a–c).
To examine whether MSK1 is involved in the anisomycin-
induced IL-6, IL-8, and TNF-a production in human
keratinocytes, we analyzed the levels of these cytokines in
the MSK1 siRNA-transfected cells. Twelve hours after
stimulation, the supernatants were examined by ELISA and
Luminex protein array. The total protein content in the cells
was used for normalization. We found in all the experiments
performed that the cells treated with MSK1 siRNA showed a
consistent reduction in IL-6, IL-8, and TNF-a production with
the average values of 51% (Po0.05), 40% (Po0.05), and
31% (Po0.05), respectively, compared with the cells treated
with nonspecific siRNA (siControl) (Figure 6d–f). The levels of
IL-1b and IFN-g in MSK1 siRNA-treated cells were also
investigated and showed no significant changes compared
with the cells treated with siControl (data not shown), even
though a significant upregulation in these cytokine levels
were seen compared with unstimulated cells.
DISCUSSION
MSK1 contribute to the regulation of gene transcription of
different pro-inflammatory genes through activation of
transcription factors such as CREB, ATF1 and NF-kB (Deak
et al., 1998). MSK1 was cloned and characterized in 1998
(Deak et al., 1998; New et al., 1999). Northern blot analysis
revealed that MSK1 is ubiquitously expressed, with mRNA
found in the eight tissues examined: heart, brain, placenta,
lung, kidney, liver, skeletal muscle, and pancreas (New et al.,
1999). To our knowledge, MSK1 has never been investigated
in the skin, nor has its role in psoriasis been investigated.
In this study, we demonstrate the presence of MSK1 total
protein in the lesional psoriatic skin as well as in the
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Figure 4. Effects of SB 202190 and PD 98059 on ERK1/2, p38, MSK1, CREB,
and ATF1 phosphorylation. (a) Cultured normal human keratinocytes were
pretreated with (a) SB 202190 (10 mM) or (b) PD 98059 (50 mM) for 30 minutes
before stimulation with IL-1b (10 ng/ml) or anisomycin (0.5 mg/ml) for 5
(phospho-ERK1/2 and phospho-p38 MAPK) and 15 minutes (phospho-MSK1,
phospho-CREB, phospho-ATF1). Whole-cell extracts (50mg of protein) were
isolated and separated onto a 10–20% gradient gel. After electroblotting, the
separated proteins were probed with (a) anti-phospho-p38, (b) anti-phospho-
ERK1/2, (a, b) anti-phospho-MSK1, or (a, b) anti-phospho-CREB/ATF1. Equal
loading was confirmed by incubating with an anti-MSK1 antibody.
Representative gels of at least three different experiments are shown.
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Figure 5. Effects of MSK1 siRNA transfection on total MSK1 protein
expression and phosphorylation of CREB. Cultured human keratinocytes
were transfected with nonspecific siControl (1 nM) or specific MSK1 siRNA
(1 nM) for 5 hours before the medium were changed. The cells were grown for
additional 48 hours before stimulation with anisomycin (0.5 mg/ml) for
15 minutes was carried out. Whole-cell extracts (40mg of protein) were
isolated and separated onto a 10–20% gradient gel. After electroblotting,
the separated proteins were probed with anti-MSK1, anti-phospho-CREB, or
anti-phospho-ATF-2. Equal loading was confirmed by incubating with an
anti-MSK2 antibody. Representative gels of at least three different
experiments are shown.
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non-lesional psoriatic skin. We show that the phosphorylated
Ser376 and Thr581 forms of MSK1 are increased in lesional
psoriatic skin compared with non-lesional psoriatic skin.
These two forms has recently been shown to bee essential for
the activation of MSK1 (Mccoy et al., 2005) The finding of
increased activation of MSK1 in lesional psoriatic skin is
interesting, because MSK1 is a downstream target of p38
MAPK (Deak et al., 1998; Roux and Blenis, 2004), and in a
very recent publication, we have demonstrated increased p38
MAPK activity in lesional psoriatic skin compared with non-
lesional psoriatic skin (Johansen et al., 2005b). Furthermore,
MSK1 has been shown to phosphorylate the NF-kB p65
subunit, leading to the stimulation of NF-kB-driven genes
(Vermeulen et al., 2003). NF-kB is one of the key regulators
of transcription of a variety of genes involved in immune and
inflammatory responses. Recently, we demonstrated that the
NF-kB DNA-binding activity is regulated in a specific manner
in psoriatic skin and that topical treatment of psoriatic skin
normalizes this abnormal NF-kB-binding activity (Johansen
et al., 2005a). In another recent published study, an
upregulation of active phosphorylated NF-kB/rel in the
epidermis from psoriatic plaques was demonstrated and a
similar downregulation during eternacept treatment (Lizzul
et al., 2005). Based on these findings, it is possible that
activation of the p38–MSK1–NF-kB signaling pathway plays a
role in the pathogenesis of psoriasis.
To further characterize the p38 MAPK/MSK1 signaling
pathway in epidermal keratinocytes, in vitro studies with
cultured normal human keratinocytes were carried out. We
showed that keratinocytes express MSK1. Upon stimulation
with anisomycin and IL-1b, MSK1(Ser376) as well as CREB
and ATF1 activation was detectable already after 5 minutes.
These findings are in accordance with results from other cell
types (Wiggin et al., 2002; Lee et al., 2003). Our data
demonstrate that the levels of the phosphorylated form of
MSK1 in the unstimulated control cells are relatively low.
A low or absent level of phosphorylated MSK1 has
been demonstrated earlier in other cell types. In cortical
neurons, phosphorylated MSK1(Ser376) was low, although
an activation of ERK also was seen (Arthur et al., 2004). A low
level of MSK1 activity in unstimulated cells has also been
demonstrated in human umbilical vein endothelial cells
(Gustin et al., 2004).
The inhibitor studies demonstrated that the activation of
MSK1, CREB, and ATF1 primarily restricts to the p38 MAPK
pathway. This is owing to our choice of stimulation agents.
Anisomycin and IL-1b are predominantly activating the p38
MAPK pathway of MSK1 rather than the ERK MAPK pathway.
We use these activators because of the increased activation of
the p38 MAPK in lesional psoriatic skin (Johansen et al., 2005b).
The absence of a specific inhibitor has made it difficult to
study the role of MSK1. Previously, H89 and Ro318220 have
been used. These two compounds inhibit, however, other
kinases, such as protein kinase A/C and casein kinase I
(Ravichandran and Burakoff, 1994; Zhong et al., 2001;
London, 2003). In the present study, siRNA technology was
used for the first time, to specific inhibit MSK1. In cultured
keratinocytes stimulated with anisomycin, siRNA inhibited
the MSK1 protein content approximately 80% and the
phosphorylation of CREB approximately 50%. This is in
accordance with the results obtained in anisomycin-stimu-
lated MSK1 ‘‘knockout’’ mice fibroblasts (Arthur and Cohen,
2000; Wiggin et al., 2002). No changes of the closely related
proteins MSK2 and MK2, both p38 MAPK downstream targets
were detected. In addition, the phosphorylation of the MSK1-
independent transcription factor ATF2 was not altered during
the transfection.
The inhibition of MSK1 and CREB phosphorylation was
accompanied by reduced levels of the anisomycin-induced
IL-6, IL-8, and TNF-a, but not of IL-1b and IFN-g production.
Anisomycin in the concentration used in this study has
previously been described to block protein synthesis (Barros
et al., 1997). However, we clearly demonstrate that
anisomycin in keratinocytes induces cytokine production,
which is in accordance with previous results from our group
(Johansen et al., 2006).
Several studies indicate the connection between the
activation of CREB and IL-6, IL-8, and TNF-a. CREB-binding
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Figure 6. Inhibition of IL-6, IL-8, and TNF-a by MSK1 siRNA. Keratinocytes were stimulated by anisomycin (0.5 mg/ml) for 4, 6, and 12 hours. The (a) IL-6,
(b) IL-8, or the (c) TNF-a protein contents were examined by ELISA. Keratinocytes were transfected with siControl (1 nM) or MSK1 siRNA (1 nM) for 48 hours
before incubation with anisomycin (0.5 mg/ml). The (d) IL-6, (e) IL-8, or the (f) TNF-a protein contents were examined 12 hours after stimulation by anisomycin
(0.5 mg/ml). Results represent mean7SD from at least three different experiments. All measurements were performed in doublets. *Po0.05 compared with
unstimulated keratinocytes. **Po0.05 compared with keratinocytes transfected with siControl.
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sites are found in the promoter regions of TNF-a (Kuprash
et al., 1999; Chong et al., 2003). IL-6 and IL-8 production was
also found to be dependent on CREB phosphorylation
(Ikewaki and Inoko, 2002; Persson et al., 2005). Our findings
demonstrate that the expression of selective pro-inflammatory
cytokines is partially controlled by MSK1 activity.
The use of siRNA technology only leads to a partial
inhibition, a ‘‘knockdown’’ and not a ‘‘knockout’’ of the
expression of the specific target protein. This could explain
the fact that only a partial inhibition of IL-6, IL-8, and TNF-a
expression was achieved during the MSK1 siRNA transfec-
tion. However, the incomplete inhibition of IL-6, IL-8, and
TNF-a, may also suggest that other kinases, downstream of
the p38 MAPK, are involved in the regulation of these
cytokines. In particular, the phosphorylation of CREB is
known to be dependent on both the MSK1 and MSK2 (Wiggin
et al., 2002). Owing to this, it would be of interest to
determine whether simultaneous inhibition of the MSK2
might result in a further inhibition of phosphorylated-CREB
and these cytokines.
In this study, we demonstrate for the first time the presence
of MSK1 in human skin. We demonstrate that MSK1 is
activated in lesional psoriatic skin compared with non-
lesional psoriatic skin. In vitro studies with cultured normal
human keratinocytes determine MSK1 to play a pivotal role
in phosphorylation of CREB and in IL-6, IL-8, and TNF-a
production. Taken together, our data indicate that MSK1 may
play a role in the pathophysiology of psoriasis and that the
p38/MSK1 signaling pathway may be a novel target in the
treatment of psoriasis.
MATERIALS AND METHODS
Biopsies
Keratome biopsies were obtained as described previously (Johansen
et al., 2004, 2005b) from lesional psoriatic skin and from non-
lesional psoriatic skin. The patients had untreated plaque-type
psoriasis and the biopsies were taken from the centre of a plaque
with moderate-to-severe psoriasis from either the upper or lower
extremities. Furthermore, paired 4 mm punch biopsies were taken
from lesional and non-lesional psoriatic skin for immunofluores-
cence. These biopsies were paraffin-embedded and 4-mm sections
were placed on slides.
The study was conducted according to the Declaration of
Helsinki Principles. The medical ethical committee of Aarhus
approved the study. Informed consent was obtained from each
patient.
Cell cultures
Normal adult human keratinocytes were obtained by trypsinization
of skin samples from patients undergoing plastic surgery as described
previously (Kragballe et al., 1985; Johansen et al., 2003). Second-
passage keratinocytes were grown in keratinocyte serum-free
medium (Invitrogen, Carlsbad, CA). The medium was changed to
keratinocyte basal medium (the same as keratinocyte serum-free
medium, but without growth factors) 24 hours before stimulation.
The cells were stimulated with anisomycin (0.5 mg/ml; Sigma
Aldrich, St Louis, MO) or IL-1b (10 ng/ml; R&D Systems, Oxon,
UK). In some experiments, the keratinocytes were pretreated with
the p38a/b inhibitor SB 202190 (10 mM; Calbiochem, San Diego, CA)
or the MAPK inhibitor PD 98059 (50 mM; Calbiochem, San Diego,
CA) 30 minutes before stimulation. A recent publication demon-
strated that SB 202190 is not necessarily specific for p38, but also
capable of binding to cholecystokinin 1 (Morel et al., 2005).
Cells were grown at 371C and 5% CO2.
Western blot analysis – cells
A solution containing 50 mM Tris-HCl, pH 6.8, 10 mM dithiothretiol,
10 mM b-glycerophosphate, 10 mM sodium flouroide, 0.1 mM sodium
orthovanadate, 10% glycerol, 2.5% SDS (BDH), and phenylmethyl-
sulfonyl fluoride and Complete-proteinase inhibitor cocktail were
used to the lysation of the cells. The lysates were boiled for
3 minutes, incubated with benzon nuclease for 15 minutes, and then
centrifuged at 13,600 g for 3 minutes at 41C and the supernatants
were removed and stored at 801C until use.
Equal amount of whole-cell protein extracts (determined by
Bradford) were separated by SDS-PAGE and blotted onto nitrocellu-
lose membranes. Membranes were incubated with either anti-
phospho-p38, -phospho-ERK, -phospho-MSK1(Ser376), -phospho-
CREB, phospho-ATF2, -CREB (Cell Signalling Technology, Beverly,
MA), -MSK2 (R&D Systems, Oxon, UK) or anti-MSK1 (Santa Cruz
Biotechnology, Santa Cruz, CA), and detected with horseradish
peroxidase-conjugated anti-rabbit or anti-goat (DAKO, Glostrup,
Denmark) in a standard ECL reaction (Cell Signalling Technology,
Beverly, MA). A biotinylated protein ladder molecular weight marker
(Cell Signalling Technology, Beverly, MA) was used for the
estimation of protein size. Densitometric analysis of the band
intensity was carried out using Kodak 1D Image Analysis Software.
Western blot analysis – keratome biopsies
The biopsies were homogenized in a cell lysis buffer (20 nM Tris-
Base, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton
X-100, 2.5 mM sodium pyrophosphate, 1 mM b-glycerolphosphate,
1 mM Na3VO4, 1 mg/ml leupeptin, and 1 mM phenylmethylsulfonyl
fluoride) and left on ice for 30 minutes. The samples were centri-
fuged at 10,000 g for 10 minutes at 41C. The supernatant constitute
the cell lysate. The Western blotting was carried out as described
in ‘‘Western blot analysis – cells’’.
Immunofluorescence
The sections were deparaffinized in xylene, hydrated through a
descending ethanol series, and for antigen unmasking the sections
were heated in 10 mM sodium citrate buffer (pH 6.0) for 1 minute at
full power and 9 minutes at medium power followed by cooling for
20 minutes. Nonspecific binding sites were blocked by 30 minutes of
incubation in blocking phosphate-buffered-saline (PBS) (0.5% non-
fat dry milk, 1% fish gelatine, 0.3% Triton X-100). Tissue sections
were immunostained with the anti-phospho-MSK1(Thr581) (Cell
Signalling Technology, Beverly, MA; no. 9595) overnight at 41C. The
next day, the sections were incubated with the secondary antibody
(Alexa Flour 594; Molecular Probes, Eugene, OR) diluted in blocking
PBS buffer for 2 hours. The sections were blocked with mouse serum
before incubation with the K14 antibody LL002 (a generous gift from
Dr I. Leigh, Cancer Research, UK), directly conjugated to Alexa
Flour 488 (Molecular Probes, Eugene, OR). Nuclear staining was
performed by mounting samples in Prolong Gold anti-fade reagent
with 40,6-diamidine-20-phenylindole dihydrochloride (Molecular
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Probes, Eugene, OR). To ensure that the staining was not owing to
nonspecific binding of the secondary antibody or owing to
nonspecific binding of rabbit IgG, negative controls were made
incubating the slides with either blocking buffer without primary
antibody or normal rabbit IgG.
siRNA transfection
Primary keratinocytes were seeded the day before transfection. Cell
density was 60–70%. Before transfection, the cells were changed to
keratinocyte basal medium. MSK1 siRNA, Pool-number M-004665-
01 (Dharmacon, Lafayette, CO), and Lipofectamine 2000 (Invitro-
gen, Carlsbad, CA) were pre-incubated with keratinocyte basal
medium. The medium-diluted siRNA and the medium-diluted
Lipofectamine 2000 incubated for 20 minutes allowing complex
formation. The siRNA:Lipofectamine complexes were added to the
cells (final MSK1 siRNA concentration: 1 nM). As control, siControl
Non-Targeting siRNA Pool (1 nM) (Dharmacon, Lafayette, CO) was
used. Five hours after transfection, the medium was changed to
keratinocyte serum-free medium. The cells were grown at 371C and
5% CO2.
RNA extraction and real-time qPCR
Total RNA was prepared from human primary keratinocytes by
lysing the cells with TRIzol (Invitrogen, Carlsbad, CA). To avoid
secondary inhibitory mRNA structures, 1mg of total RNA was mixed
with 50 pmol oligo-dT16 (in a total volume of 13 ml) and annealed at
a temperature gradient initiating at 801C and terminating at 501C.
Subsequently, cDNA synthesis was performed using Superscript II
according to the supplier’s manual (Invitrogen, Carlsbad, CA). The
annealed mRNA:oligo-d(T) was reverse transcribed in a solution
containing 1 Superscript II PCR buffer, 20 U RNasin (Promega,
Madison, WI), 0.3 mM MgCl2, 0.5 mM dNTP, and 200 U Superscript II
in a total volume of 20ml at 501C for 60 minutes. The cDNA was
diluted with 280 ml water before real-time qPCR measurements.
Real-time qPCR using an ABI 7900HT sequence detection system
and Taqman PCR primer/probes (Applied Biosystems, Foster City,
CA) was performed according to the manufacturer’s protocol. Five
microliter of the first-strand cDNA was used in an assay consisting of
10 ml Taqman Universal PCR master mix (Applied Biosystems, Foster
City, CA), 4ml water, and 1ml primer/probe. The following primer/
probes from Applied Biosystems (Assay-on-demand) were used to
detect the STAT 1 gene expression (Hs01013998_m1), the OAS2
gene expression (Hs00942650_m1), the eIF2a gene expression
(Hs01026895_m1), and the glyceraldehyde-3-phosphate dehydro-
genase gene expression (Hs99999905_m1). The conditions for the
real-time qPCR were as follows: 951C for 10 minutes and 40 cycles
of 951C for 15 seconds and 601C for 1 minute. All genes are
normalized to the expression of the housekeeping gene glyceralde-
hyde-3-phosphate dehydrogenase.
ELISA
IL-8 and TNF-a expression was measured by ELISA using 96 wells
Maxisorb (Invitrogen, Carlsbad, CA) plates, and the DuoSets ELISA
Development System (R&D Systems, Oxon, UK) according to
manufacturer’s instructions (R&D Systems). The wells were incu-
bated with 100 ml diluted Capture Antibody, 4.0 mg/ml, overnight at
room temperature. The next day, the wells were washed three times
with (PBS) containing 0.05% Tweens20 (PBST), before they were
blocked for 1 hour in 300 ml of 1% bovine serum albumin (BSA) in
PBST. The standards and the samples were diluted in either 1% BSA
in PBS, for the TNF-a ELISA, or in reagent diluent containing 0.1%
BSA, 0.05% Tweens20 in Tris-buffered Saline (20 mM Trizma base,
150 mM NaCl, pH 7.2), for the IL-8 ELISA. Hundred microliter were
added to the wells and incubated for 2 hours at room temperature.
The wells were washed three times with PBS and then incubated at
room temperature for 2 hours with 100 ml diluted detection antibody,
either 20 ng/ml (IL-8 ELISA) or 75 ng/ml (TNF-a ELISA). The wells
were washed three times in PBST, and then they were incubated
with 100ml diluted streptavidin–horseradish peroxidase (1:200) for
20 minutes. The wells were washed again in PBST and visualized by
adding 100 ml of substrate solution (R&D Systems, Oxon, UK) and
incubated for 20 minutes. The reactions were stopped by incubation
with 2 N H2SO4. Finally, the results were determined, in doublets, by
an ELISA reader (Laboratory Systems iEMS Reader MF, Copenhagen,
Denmark) at 450 nm.
Luminex protein array
Expression of IL-6, IL-1b, and IFN-g was measured using the Luminex
TechnologyTM, and a 17-plex human cytokine kit purchased from
Bio-Rad. Briefly, the filter plate was washed with assay buffer and
50 ml of freshly vortexed antibody-conjugated beads were added to
each well. The plate was washed with assay buffer and samples and
standards were added. After a brief shake (30 seconds at
1,100 r.p.m.), the plate was incubated at room temperature in the
dark for 45 minutes with light shaking (300 r.p.m.). After one wash-
step, 25ml of the detection antibody was added to each well, and the
plate was shaken and incubated as above. Subsequently, the plate
was washed and incubated for 10 minutes with 50ml of a
streptavidin–PE solution with shaking (30 seconds at 1,100 r.p.m.,
10 minutes at 300 r.p.m.). Finally, the plate was washed and 125ml
of assay buffer was added to each well and the plate shaken for
10 hours at 1,100 r.p.m. and read immediately on the Bio-Plex
machine.
Statistics
Results were expressed as mean7standard deviation. Statistical
significance (Po0.05) was assessed by Student’s t-test. To test for
normal distribution, a probability test was conducted.
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